Litigation involving US Patent 11123331

11123331

Veloxis Pharmaceuticals AS v. Zydus Cadila et al.

Open

Docket:: 1:26-cv-00467
Court:: Delaware District Court
Forum:: District Court
Filed:: 2026-04-23
Cause:: Infringement
Industry:: Medical (M)

Patents:11419823 10864199 8685998 8664239 11123331 12403095 10166190 11110081 12083103 9549918

π Veloxis Pharmaceuticals AS Δ Zydus Cadila Δ Zydus Lifesciences Ltd

Infringed product

The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.

Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.

active

Docket:: 1:22-cv-00909
Court:: District of Delaware
Filed:: 2022-07-07

Patents:11123331

π Veloxis Pharmaceuticals, Inc.Δ Accord Healthcare, Inc.Δ Intas Pharmaceuticals LTD

Veloxis Pharmaceuticals, Inc. filed suit alleging patent infringement due to the defendants' submission of Abbreviated New Drug Applications (ANDA) for generic tacrolimus extended-release tablets. Veloxis is seeking favorable judgment, an order preventing manufacturing, and damages.

Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd.

active

Docket:: 24-0784
Court:: District of Delaware
Filed:: 2024-07-03

Patents:11123331

π Veloxis Pharmaceuticals, Inc.Δ Alkem Labs. Ltd.

This appears to be an ANDA case concerning Envarsus XR® (tacrolimus extended-release tablets). The case is currently active.

Untitled case

active

Docket:: 1:24-cv-00726
Court:: Delaware District Court

Patents:11123331

This is an active litigation case in the Delaware District Court involving US Patent 11,123,331.